AVITA Medical's RECELL Platform Recognized for Surgical Innovation in 2025 MedTech Breakthrough Awards
VALENCIA, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering a portfolio of transformative solutions, today announced that RECELLⓇ, including RECELLⓇ GO, has been recognized as the “Best New Technology Solution – Surgical” in the 2025 MedTech Breakthrough Awards.
AVITA Medical, Inc. (RCEL) Q1 2025 Earnings Call Transcript
AVITA Medical, Inc. (NASDAQ:RCEL ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Jessica Ekeberg - Director, Investor Relations Jim Corbett - Chief Executive Officer David O'Toole - Chief Financial Officer Conference Call Participants Brooks O'Neil - Lake Street Capital Markets Chris Kallos - MST Access Operator Good day, and thank you for standing by. Welcome to AVITA Medical First Quarter 2025 Earnings Conference Call.
AVITA Medical to Announce First Quarter 2025 Financial Results
VALENCIA, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound company delivering transformative solutions, today announced that it will report its first quarter 2025 financial results after the close of the U.S. financial markets on Thursday, May 8, 2025.
AVITA Medical to Present Breakthrough Clinical Data in Burn and Wound Care at ABA 2025
VALENCIA, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering a portfolio of transformative solutions, today announced 16 abstracts to be presented at the American Burn Association (ABA) 2025 Annual Meeting, taking place April 8-11 in Phoenix, Arizona.
AVITA Medical Announces Exclusive Manufacturing and Distribution Agreements with Stedical Scientific
AVITA Medical announces new manufacturing agreement and amended distribution agreement with Stedical Scientific to further commercialization of PermeaDerm.
Wall Street Analysts Predict a 52.64% Upside in Avita Medical (RCEL): Here's What You Should Know
The mean of analysts' price targets for Avita Medical (RCEL) points to a 52.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
After Sales Rebound In January, AVITA Is Set Up For A Monster Year
After Sales Rebound In January, AVITA Is Set Up For A Monster Year
AVITA Medical to Host Investor Webinar Briefing
AVITA Medical invites shareholders and prospective investors to attend its investor webinar briefing and presentation on February 18, 2025 at 2:00PM PT.
AVITA Medical, Inc. (RCEL) Q4 2024 Earnings Call Transcript
AVITA Medical, Inc. (NASDAQ:RCEL ) Q4 2024 Earnings Conference Call February 13, 2025 4:30 PM ET Company Participants Jessica Ekeberg - Director of Investor Relations Jim Corbett - Chief Executive Officer David O'Toole - Chief Financial Officer Conference Call Participants Matthew Park - Cantor Fitzgerald Ryan Zimmerman - BTIG Brooks O'Neil - Lake Street Capital Markets Joshua Jennings - TD Cowen Operator Good day, and thank you for standing by. Welcome to the AVITA Medical Fourth Quarter 2024 Earnings Conference Call.
AVITA Medical Reports Fourth Quarter and Full Year 2024 Financial Results
VALENCIA, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today reported financial results for the fourth quarter and full year ended December 31, 2024.
Investors Burned By AVITA Medical's Sales Miss: I'm Even More Bullish
AVITA Medical's stock plummeted 36.4% after a significant Q4 sales miss, highlighting a pattern of guidance misses. Management's breakeven target shifted to Q4 2025. It also gave 2025 sales guidance of $100-$106 million. The Company will be forced to repay its $40 million OrbiMed loan if its sales follow my projections and company guidance.
AVITA Medical: A Dip Buy As 2025 Looks Bullish With Cohealyx And RECELL GO Mini
AVITA Medical: A Dip Buy As 2025 Looks Bullish With Cohealyx And RECELL GO Mini
